These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Metabolites of mercaptopurine in red blood cells: a relationship between 6-thioguanine nucleotides and 6-methylmercaptopurine metabolite concentrations in children with lymphoblastic leukemia. Chrzanowska M; Kolecki P; Duczmal-Cichocka B; Fiet J Eur J Pharm Sci; 1999 Aug; 8(4):329-34. PubMed ID: 10425383 [TBL] [Abstract][Full Text] [Related]
3. DNA-thioguanine nucleotide concentration and relapse-free survival during maintenance therapy of childhood acute lymphoblastic leukaemia (NOPHO ALL2008): a prospective substudy of a phase 3 trial. Nielsen SN; Grell K; Nersting J; Abrahamsson J; Lund B; Kanerva J; Jónsson ÓG; Vaitkeviciene G; Pruunsild K; Hjalgrim LL; Schmiegelow K Lancet Oncol; 2017 Apr; 18(4):515-524. PubMed ID: 28258828 [TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and metabolism of thiopurines in children with acute lymphoblastic leukemia receiving 6-thioguanine versus 6-mercaptopurine. Erb N; Harms DO; Janka-Schaub G Cancer Chemother Pharmacol; 1998; 42(4):266-72. PubMed ID: 9744770 [TBL] [Abstract][Full Text] [Related]
5. Intensification of mercaptopurine/methotrexate maintenance chemotherapy may increase the risk of relapse for some children with acute lymphoblastic leukemia. Schmiegelow K; Björk O; Glomstein A; Gustafsson G; Keiding N; Kristinsson J; Mäkipernaa A; Rosthøj S; Szumlanski C; Sørensen TM; Weinshilboum R J Clin Oncol; 2003 Apr; 21(7):1332-9. PubMed ID: 12663723 [TBL] [Abstract][Full Text] [Related]
6. Leucocyte versus erythrocyte thioguanine nucleotide concentrations in children taking thiopurines for acute lymphoblastic leukaemia. Lancaster DL; Patel N; Lennard L; Lilleyman JS Cancer Chemother Pharmacol; 2002 Jul; 50(1):33-6. PubMed ID: 12111109 [TBL] [Abstract][Full Text] [Related]
7. Thioguanine versus mercaptopurine for therapy of childhood lymphoblastic leukaemia: a comparison of haematological toxicity and drug metabolite concentrations. Lancaster DL; Lennard L; Rowland K; Vora AJ; Lilleyman JS Br J Haematol; 1998 Jul; 102(2):439-43. PubMed ID: 9695957 [TBL] [Abstract][Full Text] [Related]
8. The impact of high-dose methotrexate on intracellular 6-mercaptopurine disposition during interval therapy of childhood acute lymphoblastic leukemia. Adam de Beaumais T; Dervieux T; Fakhoury M; Medard Y; Azougagh S; Zhang D; Yakouben K; Jacqz-Aigrain E Cancer Chemother Pharmacol; 2010 Sep; 66(4):653-8. PubMed ID: 20033410 [TBL] [Abstract][Full Text] [Related]
9. Effect of methotrexate polyglutamates on thioguanine nucleotide concentrations during continuation therapy of acute lymphoblastic leukemia with mercaptopurine. Dervieux T; Hancock M; Evans W; Pui CH; Relling MV Leukemia; 2002 Feb; 16(2):209-12. PubMed ID: 11840287 [TBL] [Abstract][Full Text] [Related]
10. Mercaptopurine metabolite levels are predictors of bone marrow toxicity following high-dose methotrexate therapy of childhood acute lymphoblastic leukaemia. Vang SI; Schmiegelow K; Frandsen T; Rosthøj S; Nersting J Cancer Chemother Pharmacol; 2015 May; 75(5):1089-93. PubMed ID: 25788208 [TBL] [Abstract][Full Text] [Related]
11. Measures of 6-mercaptopurine and methotrexate maintenance therapy intensity in childhood acute lymphoblastic leukemia. Nielsen SN; Grell K; Nersting J; Frandsen TL; Hjalgrim LL; Schmiegelow K Cancer Chemother Pharmacol; 2016 Nov; 78(5):983-994. PubMed ID: 27600880 [TBL] [Abstract][Full Text] [Related]
12. A comparison of red blood cell thiopurine metabolites in children with acute lymphoblastic leukemia who received oral mercaptopurine twice daily or once daily: a Pediatric Oncology Group study (now The Children's Oncology Group). Bell BA; Brockway GN; Shuster JJ; Erdmann G; Sterikoff S; Bostrom B; Camitta BM; Pediatr Blood Cancer; 2004 Aug; 43(2):105-9. PubMed ID: 15236274 [TBL] [Abstract][Full Text] [Related]
13. Risk of relapse in childhood acute lymphoblastic leukemia is related to RBC methotrexate and mercaptopurine metabolites during maintenance chemotherapy. Nordic Society for Pediatric Hematology and Oncology. Schmiegelow K; Schrøder H; Gustafsson G; Kristinsson J; Glomstein A; Salmi T; Wranne L J Clin Oncol; 1995 Feb; 13(2):345-51. PubMed ID: 7531219 [TBL] [Abstract][Full Text] [Related]
14. Is 6-thioguanine more appropriate than 6-mercaptopurine for children with acute lymphoblastic leukaemia? Lennard L; Davies HA; Lilleyman JS Br J Cancer; 1993 Jul; 68(1):186-90. PubMed ID: 8318412 [TBL] [Abstract][Full Text] [Related]
15. Dynamics of leucocyte DNA thioguanine nucleotide levels during maintenance therapy of childhood acute lymphoblastic leukemia. Larsen RH; Hjalgrim LL; Degn M; Nersting J; Als-Nielsen B; Grell K; Schmiegelow K Cancer Chemother Pharmacol; 2021 Jul; 88(1):53-60. PubMed ID: 33754188 [TBL] [Abstract][Full Text] [Related]
16. Use of allopurinol in children with acute lymphoblastic leukemia to reduce skewed thiopurine metabolism. Brackett J; Schafer ES; Leung DH; Bernhardt MB Pediatr Blood Cancer; 2014 Jun; 61(6):1114-7. PubMed ID: 24376133 [TBL] [Abstract][Full Text] [Related]
17. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lennard L; Lilleyman JS; Van Loon J; Weinshilboum RM Lancet; 1990 Jul; 336(8709):225-9. PubMed ID: 1973780 [TBL] [Abstract][Full Text] [Related]
18. Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukaemia. Lilleyman JS; Lennard L Lancet; 1994 May; 343(8907):1188-90. PubMed ID: 7909868 [TBL] [Abstract][Full Text] [Related]
19. Mercaptopurine in childhood leukaemia: the effects of dose escalation on thioguanine nucleotide metabolites. Lennard L; Welch J; Lilleyman JS Br J Clin Pharmacol; 1996 Oct; 42(4):525-7. PubMed ID: 8904630 [TBL] [Abstract][Full Text] [Related]
20. Variable correlation between 6-mercaptopurine metabolites in erythrocytes and hematologic toxicity: implications for drug monitoring in children with acute lymphoblastic leukemia. Innocenti F; Danesi R; Favre C; Nardi M; Menconi MC; Di Paolo A; Bocci G; Fogli S; Barbara C; Barachini S; Casazza G; Macchia P; Del Tacca M Ther Drug Monit; 2000 Aug; 22(4):375-82. PubMed ID: 10942174 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]